Sage Therapeutics to end Huntington’s disease trial after key therapy fails again
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as ...
Pharmaceutical Technology59m
Parkinson’s disease cases to reach 3.15 million in 7MM by 2033
Diagnosed prevalent cases of Parkinson’s disease will grow at 1.94% annually in the seven major markets between 2023 and 2033 ...